Experimental Alzheimer's drug improved cognition and behavior
BioWorld - 02-Feb-2021With positive results in phase 2b, simufilam to begin phase III in second half of 2021
Join the club for FREE to access the whole archive and other member benefits.
Chairman, President, CEO and Founder of Cassava Sciences
Remi Barbier, the Company’s founder, has served as President, Chief Executive Officer and Chairman of the Board of Directors since the Company’s inception in May 1998. Prior to that time, Mr. Barbier helped in the growth or founding of Exelixis Inc., a publicly-traded drug development company, ArQule, Inc., a drug development company acquired by Merck & Co., and EnzyMed, Inc., a chemistry company acquired by Albany Molecular Research, Inc. Mr. Barbier is a trustee emeritus of the Carnegie Institute of Washington, the Santa Fe Institute and the Advisory Board of the University of California Institute for Quantitative Biosciences. He is on the board of BioVentures LLC, a life science incubator at the University of Arkansas for Medical Sciences.
Visit website: https://www.cassavasciences.com/management
See also: Cassava Sciences - Company with mission to detect and treat neurodegenerative diseases, such as Alzheimer’s disease
Details last updated 04-Feb-2021
With positive results in phase 2b, simufilam to begin phase III in second half of 2021